“Selecting the Optimal Treatment Line for CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer”, Вопр. онкол., vol. 72, no. 3, p. OF-2455, Jul. 2026, doi: 10.37469/0507-3758-2026-72-3-OF-2455.